Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734292 · ClinicalTrials.gov registry record · Phase 2
Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma
A Phase 2 study, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT00734292: Completed Phase 2 study, sponsored by SkyePharma.
NCT00734292 is a Phase 2 study that has completed, run by SkyePharma. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734292, a Phase 2 study, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
Interventions
- DRUG fluticasone propionate, formoterol fumarate
- OTHER fluticasone propionate, formoterol fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00734292
The ClinicalTrials.gov registry entry for NCT00734292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SkyePharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluticasone propionate, formoterol fumarate is the first listed.
NCT00734292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00734292 about?
NCT00734292 is a clinical study titled "Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma". The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.
What is the current status of trial NCT00734292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00734292?
The interventions under investigation include: fluticasone propionate, formoterol fumarate (DRUG), fluticasone propionate, formoterol fumarate (OTHER).
Who is sponsoring clinical trial NCT00734292?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.